SUNNYVALE, Calif., July 5, 2016 /PRNewswire/ -- Cepheid (Nasdaq: CPHD) today applauded the opening of the 10 Hammersmith Broadway Sexual Health clinic in London, England.
The Hammersmith Clinic is the next in a series of new clinics developed by the Chelsea & Westminster NHS Foundation Trust. This is the same team behind the Dean Street Express, a highly acclaimed sexual health clinic located in London's Soho district that has been challenging the model for sexually transmitted infection (STI) testing and public health since it opened its doors in February 2014. 10 Hammersmith Broadway and Dean Street Express offer drop-in service and high throughput testing on site for a number of STIs, including CT/NG, HIV, and syphilis.
Like Dean Street Express, the 10 Hammersmith Broadway clinic uses Cepheid's GeneXpert® System, the world's most popular molecular diagnostics' instrument. Testing with the GeneXpert Infinity system is completed entirely on-site, significantly reducing the time to diagnosis, and delivering accurate results that can be shared with patients in hours, rather than days to weeks. This process minimizes time and worry for patients, reduces transmission risk, and enables more immediate treatment.
The 10 Hammersmith Broadway clinic is the new home for the West London Centre for Sexual Health and provides Londoners with even greater accessibility to high quality sexual health diagnostics. These clinics, empowered by the rapid test capability of the GeneXpert System, will provide broad access to patients throughout the city. The Dean Street Express clinic alone has screened over 200,000 patients in the past two years, and last week received a Service Excellence Award from Cepheid.
"The innovative, patient-focused clinics Dean Street Express and 10 Hammersmith Broadway deliver actionable information in a way that is transformative for patients at risk for STIs," said David Persing, M.D., Ph.D., Cepheid's Chief Medical and Technology Officer. "Patients appreciate getting their negative results back quickly, and the clinicians are happy with the short time to positive results because they can often avoid empiric therapy. Healthcare professionals know that if they treat early and effectively, they can reduce or even prevent complications of STIs and intercept subsequent transmission events."
The 10 Hammersmith Broadway and Dean Street Express clinics offer customer-friendly and discrete sexual health testing that is highly effective in screening for STIs and can result in a higher rate of case detection in both symptomatic and asymptomatic patients. Further clinic developments are scheduled for later this year.
Based in Sunnyvale, Calif., Cepheid (Nasdaq: CPHD) is a leading molecular diagnostics company that is dedicated to improving healthcare by developing, manufacturing, and marketing accurate yet easy to use molecular systems and tests. By automating highly complex and time-consuming manual procedures, the company's solutions deliver a better way for institutions of any size to access the full power of molecular diagnostics. The company's systems enable rapid, sophisticated testing solutions for infectious diseases, oncology, and genetic conditions by automating otherwise complex manual laboratory procedures. Through its strong molecular biology capabilities, the company is focusing on those applications where accurate, rapid, and actionable test results are needed most, such as managing infectious diseases and cancer. For more information, visit www.cepheid.com.
Forward Looking Statements
This press release contains forward-looking statements that are not purely historical regarding Cepheid's or its management's intentions, beliefs, expectations and strategies for the future, including those relating to the role and effectiveness of certain sexual health clinics and Cepheid GeneXpert systems in sexual health services, particularly in STD screening, treatment and transmission prevention; the continued use of Cepheid systems in such clinics; future availability and accessibility of testing locations; and future performance, sensitivity, speed, accuracy, diagnostic utility and clinical efficacy of the GeneXpert tests. Because such statements deal with future events, they are subject to various risks and uncertainties, and actual results could differ materially from Cepheid's current expectations. Factors that could cause actual results to differ materially include risks and uncertainties such as those relating to: test performance in the field; utilization of the Company's tests by clinicians and future changes in medical practice and protocols; the Company's ability to successfully and timely develop new products; the completion of clinical trials for new products successfully and in a timely manner; uncertainties related to the United States FDA, European and other regulatory processes; the Company's ability to successfully introduce and sell products in global markets; the Company's research and development budget; unforeseen supply, development and manufacturing problems; the potential need for additional intellectual property licenses for tests and other products and the terms of such licenses; the impact of competitive products and pricing; the costs of product components and other factors affecting product pricing; the Company's ability to manage geographically-dispersed operations; and underlying regulatory, political and market conditions worldwide. Readers should also refer to the section entitled "Risk Factors" in Cepheid's Annual Report on Form 10-K, its most recent Quarterly Report on Form 10-Q, and its other reports filed with the Securities and Exchange Commission.
All forward-looking statements and reasons why results might differ included in this release are made as of the date of this press release, based on information currently available to Cepheid, and Cepheid assumes no obligation to update any such forward-looking statement or reasons why results might differ.
For Cepheid Media & Investor Inquiries:
Jacquie Ross, CFA